News | August 02, 2024
GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
Strong topline growth driven by solid performance across key brands.
Strong topline growth driven by solid performance across key brands.
Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Decision on EU marketing authorisation for this population expected by September 2024
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024
The inspections concluded with no Form 483 observations or significant critical findings
Subscribe To Our Newsletter & Stay Updated
